On February 25, 2020 ExCellThera Inc., a clinical stage biotechnology company delivering molecules and bioengineering solutions to expand stem and immune cells for therapeutic use, recently reported preliminary data from the Phase 2 trial of its ECT-001 Cell Therapy in patients with high-risk leukemia and myelodysplasia (MDS) (Press release, ExCellThera, FEB 25, 2020, View Source [SID1234554696]). The preliminary data was presented at the 2020 Transplant and Cellular Therapy (TCT) Annual Meeting in Orlando, Florida, and demonstrates excellent leukemia free survival in patients with high-risk leukemia and myelodysplasia.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ECT-001 Cell Therapy is a combination of a small molecule, UM171, and an optimized culture system. The technology, capable of expanding the number of stem and immune cells exponentially in as little as seven days, is used in novel curative cord blood transplant therapies for patients with hematological malignancies, allowing more rapid engraftment, greatly reduced incidence of transplant-related mortality, low risk of chronic graft-versus-host disease and low risk of relapse, resulting in better outcomes for patients.
"The preliminary data from the ECT-001 Cell Therapy Phase 2 trial suggests excellent leukemia free survival for high-risk patients with leukemias and myelodysplasia; this data is extremely encouraging as these leukemia free survival results are not seen for this high-risk patient population under the current standard or care," said Dr. Guy Sauvageau, CEO and founder of ExCellThera. "This preliminary Phase 2 data in high-risk leukemias and myelodysplasia adds to the body of excellent clinical data for ECT-001, which has been dosed in over 50 patients to date. It further validates the introduction of the cryopreserved ECT-001 product, which will enable us to perform multi-centre trials and eventually provide global patient access to our cell therapy product."
ExCellThera expects that enrolment in Phase 2 trials of its ECT-001 Cell Therapy will be competed in 2020 and intends to continue dialogue with the FDA under the auspices of the RMAT designation on a pivotal registration-enabling study, and to have discussions with the European Medicines Agency for development in Europe.
Data presented at the 2020 Transplant and Cellular Therapy (TCT) Annual Meeting
Presenter: Sandra Cohen, MD, Hôpital Maisonneuve-Rosemont/Université de Montréal
Updated data from Phase 1/2 trial (completed) of ECT-001 Cell Therapy in patients with hematological malignancies:
Clinically viable with a rapid 7-day expansion and small culture volume
Accelerates clinically relevant engraftment (100 neutrophils at D+9.5) regardless of cord blood unit size
Reduced hospitalization length and fever (last day of fever D+7.5)
A single expanded cord is possible for all patients, with better HLA matching
Access to up to 50% of cord blood units in banks for 70kg patient
Low incidence of transplant related mortality (5%)
Excellent chronic GVHD-relapse-free survival (CRFS) of 74% at 33 months
Preliminary Data from Phase 2 trial (ongoing) of ECT-001 Cell Therapy in patients with high-risk leukemia and myelodysplasia
To date, seven (7) high-risk patients dosed with ECT-001 Cell Therapy
Preliminary data suggests excellent leukemia free survival